Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.41 |
| ▸ | OGA | O60502 | 6/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154316 | 0.89 | OGA (0.43) | OGAFFAR1 | |
| SCHEMBL16299424 | 0.86 | OGA (0.43) | OGAFFAR1 | |
| SCHEMBL12892175 | 0.81 | GPR119 (0.44) | OGA | |
| SCHEMBL10154273 | 0.74 | OGA (0.39) | OGA | |
| SCHEMBL2963567 | 0.74 | ITGB3 (0.57) | — | |
| SCHEMBL2928639 | 0.74 | ITGB3 (0.71) | — | |
| SCHEMBL31150973 | 0.73 | REN (0.41) | FFAR1 | |
| SCHEMBL15971975 | 0.71 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL15971974 | 0.71 | FFAR1 (0.62) | FFAR1 | |
| SCHEMBL8346388 | 0.71 | GPR119 (0.43) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879881-B2 | 1-[[3-[(1,4,5,6-Tetrahydro-2-pyrimidinyl)amino]phenyl]acetyl]-4-piperidinepropanoic acid; new class of selective modulator of beta 3, beta 5 or dual integrin receptors; anticarcinogenic, antiinflammatory, antidiabetic agent | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-01 | — | — | US | disclosed |
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058359-A1 | Piperidinyl compounds that selectively bind integrins | ITGB3, ITGAV, ITGA2B | SLC6A2 4137/4885SLC6A4 3832/4885SLC6A3 3997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.